

Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS



Richard Lemal, MD^{a,*}, Guillemette Fouquet, MD^{b,*}, Louis Terriou, MD^c, Mélanie Vaes, MD^{d,e}, Cristina Bulai Livideanu, MD^f, Laurent Frenzel, MD, PhD^g, Stéphane Barete, MD, PhD^h, Danielle Canioni, MDⁱ, Ludovic Lhermitte, MD, PhD^j, Julien Rossignol, MD, PhD^{k,l}, Michel Arock, PharmD, PhD^{m,n}, Patrice Dubreuil, PhD^o, Olivier Lortholary, MD, PhD^p, and Olivier Hermine, MD, PhD^{b,g,k} *Clermont-Ferrand, Paris, Lille, Toulouse, Villejuif, Cachan, and Marseille, France; Brussels and La Louvière, Belgium*

What is already known about this topic? Clinical experience of omalizumab in mast cell disorders is limited, with mainly case reports and a 14-patient retrospective series testifying for its efficacy in recurrent anaphylaxis, venom immunotherapy, and mast cell activation symptoms.

What does this article add to our knowledge? We prospectively surveyed 55 patients with a systemic mast cell disorder receiving omalizumab, following the same administration scheme. The overall response rate was 78.2% with a very favorable safety profile.

How does this study impact current management guidelines? This real-life study describes the symptoms that encompass the best response, the median time to response, and it provides guidelines about optimal modalities of omalizumab administration in mast cell disorders.

BACKGROUND: Patients with mast cell diseases may suffer from various distressing symptoms, which can be insufficiently controlled with available therapies, severely affecting their quality of life. There is a need for new and safe treatment options for these patients.

OBJECTIVES: We aimed to evaluate safety and efficacy of omalizumab administration in patients with a symptomatic mast cell disorder.

METHODS: We included 55 patients with a mast cell disorder associated with debilitating symptoms who received omalizumab treatment between January 2015 and December 2017, after a multidisciplinary team meeting at the French National Reference Center for Mastocytosis.

RESULTS: A complete response was achieved for 1 patient (1.8%), a major response for 30 patients (54.5%), and a partial response for 12 patients (21.8%), resulting in an overall best response rate of 78.2% (43 of 55 patients). The response was persistent at least 3 months in 33 of 43 responding patients (76.7%). At the last follow-up, the final overall response rate was 58.2% (32 of 55 patients). Median time to first response was 2 months and median time to best response was 6 months. Omalizumab was dramatically effective on all superficial and general vasomotor symptoms and on most gastrointestinal or urinary symptoms, and partially effective on most neuropsychiatric symptoms. Safety profile was acceptable, except for one

^aHistocompatibility Laboratory, EA 7453—Université Clermont Auvergne, CHU de Clermont-Ferrand, Clermont-Ferrand, France

^bImagine Institute, INSERM U1163 and CNRS ERL 8654, Paris Descartes University, Sorbonne Paris Cité, Paris, France

^cDepartment of Internal Medicine and Clinical Immunology, Hôpital Huriez, CHRU Lille, Lille, France

^dDepartment of Hematology, Université Libre de Bruxelles, Hôpital Erasme, Brussels, Belgium

^eDepartment of Hematology, Université Libre de Bruxelles, CHU Tivoli, La Louvière, Belgium

^fFrench Reference Center for Mastocytosis (CEREMAST), Department of Dermatology, Hôpital Larrey, CHU Toulouse, Toulouse, France

^gDepartment of Hematology, Necker Children's Hospital, APHP, Paris, France

^hFrench Reference Center for Mastocytosis (CEREMAST), Dermatology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France

ⁱPathology Department, Necker Children's Hospital, APHP, Paris, France

^jHematology Department, Necker Children's Hospital, APHP, Paris, France

^kFrench Reference Center for Mastocytosis (CEREMAST), Necker Children's Hospital, APHP, Paris, France

^lHematology Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France

^mLBPA CNRS UMR8113, Ecole Normale Supérieure de Paris-Saclay, Cachan, France

ⁿHematology Department, Pitié-Salpêtrière Hospital, APHP, Paris, France

^oCentre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France

^pNecker Pasteur Center for Infectious Diseases and Tropical Medicine, Necker Children's Hospital, APHP, Paris, France

No funding was received for this work.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication October 9, 2018; revised February 24, 2019; accepted for publication March 12, 2019.

Available online April 5, 2019.

Corresponding author: Richard Lemal, MD, CHU de Clermont-Ferrand, Unité d'histocompatibilité — Centre de Biologie, 58, rue Montalembert, 63000 Clermont-Ferrand, France. E-mail: rlemal@chu-clermontferrand.fr.

* These authors contributed equally to this work.

2213-2198

© 2019 American Academy of Allergy, Asthma & Immunology

<https://doi.org/10.1016/j.jaip.2019.03.039>

Abbreviations used

CEREMAST- French National Reference Center for Mastocytosis

CM- Cutaneous mastocytosis

CR- Complete response

FDA- Food and Drug Administration

ISM- Indolent systemic mastocytosis

MCA- Mast cell activation

MCAS- Mast cell activation syndrome

MMAS- Monoclonal MCAS

MR- Major response

PR- Partial response

SM- Systemic mastocytosis

SM-AHN- Systemic mastocytosis with associated hematologic neoplasm

SSM- Smoldering SM

WHO- World Health Organization

severe adverse event (edema of the larynx and dyspnea after the first injection of omalizumab). Side effects were reported in 16 patients (29%), mainly of low to mild intensity, yet causing interruption of treatment in 5 patients (9%).

CONCLUSION: Omalizumab seems to be a useful therapeutic option to control mast cell—mediator symptoms and displays a favorable safety profile. © 2019 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2019;7:2387-95)

Key words: Omalizumab; Mast cell disorders; Mastocytosis; IgE

Mast cells are effector cells involved in allergic and inflammatory reactions.¹⁻³ They derive from myeloid stem cells, and then migrate in tissues and organs.¹ Mast cells are a well-known source for many proinflammatory mediators (such as histamine, tryptase, prostaglandin D₂, platelet-activating factor, leukotrienes, various cytokines, and chemokines) and express the high-affinity IgE receptor FcεRI.¹⁻³ Once activated by an allergen that aggregates IgE and FcεRI complexes, or by non-IgE-related stimuli, mast cells self-activate and release their mediators, which can cause many local and systemic symptoms.

Systemic mastocytosis (SM) is a heterogeneous hematological neoplasm characterized by clonal expansion and accumulation of mast cells in different tissues, including the bone marrow, the skin, the gastrointestinal tract, the liver, and the spleen.¹ SM is opposed to cutaneous mastocytosis (CM) where only the skin is involved, even though most adult patients with CM have SM. SM is further divided into several subcategories of increasing severity: indolent SM (ISM), smoldering SM (SSM), SM with associated hematologic neoplasm (SM-AHN), aggressive SM, and mast cell leukemia.⁴ Some patients display typical clinical symptoms of mast cell activation (MCA), but do not meet the criteria for mastocytosis: these patients are diagnosed with another mast cell disorder called mast cell activation syndrome (MCAS), which can be clonal (if *KIT* mutation [mandatory] ± aberrant phenotype [CD2 and/or CD25] is proven) (MMAS) or nonclonal.⁵

In ISM, SSM, some SM-AHN, MMAS, or nonclonal MCAS, clinical symptoms caused by MCA are often in the foreground, and can be very diverse ranging from chronic mild pruritus, musculoskeletal pain, fluctuating abdominal cramping, and diarrhea, to acute episodes of potentially life-threatening

anaphylaxis.^{1,5} Patients with mast cell disorders can also present neuropsychiatric symptoms with unknown pathophysiological mechanisms.

Several pharmacologic agents can target MCA symptoms such as antihistamines, corticosteroids, cromolyn sodium, or leukotriene inhibitors. When those agents are insufficient to control symptoms, targeting mast cells with tyrosine kinase inhibitors, immunomodulatory, or cyto-reductive therapies such as imatinib, masitinib, alpha-interferon, or cladribine can be necessary^{4,6,7} but some patients can relapse, experience adverse events, or become refractory to these therapies. Moreover, these therapies should only be used in patients with mastocytosis and not in other mast cell disorders. Uncontrolled MCA symptoms can severely affect the quality of life of patients, and there is a great need for alternative and safe treatment options.⁸

Omalizumab is a humanized anti-IgE monoclonal antibody already approved for the treatment of allergic asthma and chronic spontaneous urticaria.⁹⁻¹¹ In these diseases, omalizumab binds to free IgE, decreases the expression of FcεRI, and therefore increases the threshold for degranulation of mast cells and basophils.¹⁰

Clinical experience of omalizumab in mast cell disorders is limited, with mainly case reports testifying for its efficacy in recurrent anaphylaxis.¹²⁻¹⁹ It has also been shown to help control reactions to venom immunotherapy.¹⁷ In some cases, a “flare” effect has been observed after injection of omalizumab,²⁰ which pleads for a first in-hospital administration. More recently, a 14-patient cohort study evaluated the efficacy and safety of omalizumab in SM.²¹ This study reported a promising efficacy of omalizumab in SM, especially in anaphylaxis but with improvement of other MCA symptoms and quality of life as well, along with a favorable safety profile.

We aimed to confirm these results by analyzing our national cohort of 55 patients who received omalizumab since January 2015, within the institutional framework of the French National Reference Center for Mastocytosis (CEREMAST).

METHODS

Patients

From January 2015 to December 2017, the national multidisciplinary expert team from the CEREMAST recommended treatment with omalizumab for 65 patients with symptomatic mast cell disorder, treated in 11 different centers in France and Belgium. Patients had severe or debilitating symptoms refractory to classical treatments of mast cell disorders, including antihistamines, cromolyn sodium, or leukotriene inhibitors. According to CEREMAST rules of functioning, patients with such treatment decision were prospectively surveyed in the CEREMAST national database, to record efficacy and safety data. The use of this computerized database²² to store personal information was authorized by the French National Data Protection Commission (CEREMAST authorization: CNIL: No1445939 [October 29, 2010]).

In January 2018, we screened these 65 eligible patients, and the different centers were contacted to update data with the last follow-up. We included patients who received at least 1 injection of omalizumab. Nine patients who did not receive omalizumab, who were lost from follow-up, or for whom data were deemed insufficient were excluded from this study. One patient with SM-AHN was also excluded from this study. We retained 55 of 65 patients with a confirmed diagnosis of mast cell disorder according to the World

Health Organization (WHO) criteria²³ ($n = 40$ patients) and with clonal and nonclonal MCAS ($n = 1$ and $n = 14$ patients). MCAS was diagnosed according to recommendations, by the association of typical clinical symptoms, increase in serum total tryptase by at least 20% above baseline plus 2 ng/mL during or within 4 hours after a symptomatic period, and response of clinical symptoms to histamine receptor blockers (HR1 $\pm$ HR2 inverse agonists) or “MC-targeting” agents such as cromolyn 1.⁵

All 55 patients were informed that they received a drug not registered either for mastocytosis or for MCAS, but that could be prescribed after recommendation from a multidisciplinary team meeting at the CEREMAST. All patients gave their consent for this prospective survey.

Clinical and biological data were collected from the CEREMAST database for all 55 patients, and completed with medical files and with a descriptive questionnaire sent to the clinician in charge of the treated patient(s). The study was conducted according to the Declaration of Helsinki.

Omalizumab therapy

The recommended starting dose of omalizumab was 150 mg every 2 weeks subcutaneously, without taking into account patient weight or total IgE level. Patients were strongly encouraged to continue their conventional therapy during omalizumab therapy. First injection was always performed at the hospital, and the following doses could be injected at home. The rhythm of physician’s supervision was every 4 to 6 weeks during the first 3 months and then every 3 to 6 months depending on tolerance and efficacy. A dose escalation to a maximum of 300 mg every 2 weeks was allowed to improve a partial efficacy. A weekly administration of omalizumab was permitted (150 mg/week), in case of reoccurrence of symptoms before the following dose of omalizumab, in a patient responding to therapy. This reappearance of symptoms a few days before the following dose of omalizumab was assessed by the patient and his or her physician. It should be noted that there is no proof of the efficacy of these regimens (dose escalation or weekly dosing) and that they are not recommended outside of a clinical trial. Treatment was given as long as it was effective and well tolerated.

Efficacy assessment: symptoms improvement

All symptoms were assessed before and during treatment, from medical files and/or via an assessment questionnaire sent to the clinician in charge of the treated patients. We collected all symptoms present before treatment, and attributed the number 1 for all existing symptoms at baseline. Then, for each symptom, we determined the evolution on treatment, including time to first response and time to best response.

To semiquantitatively evaluate the symptoms evolution, we established a “symptom score” summing up the response for each symptom under omalizumab therapy:

- 1.5: Worsening of the symptom.
- 1: No change.
- 0.75: Slight improvement.
- 0.5: Substantial improvement.
- 0.25: Dramatic improvement.
- 0: Complete disappearance of the symptom.

Quality of life assessment with classical forms was not mandatory in this real-life study; thus, the effect of omalizumab on quality of life was not assessable.

Efficacy assessment: depth of response

Responses were assigned at the time of best response, from the “symptom score.” A complete response (CR) was defined as the resolution of all preexisting symptoms. A major response (MR) was defined as a decrease superior to 50% of preexisting symptoms, according to symptom score. A partial response (PR) was defined as a decrease of 10% to 50% of preexisting symptoms, according to symptom score. The absence of response was defined as a decrease of less than 10% of preexisting symptoms, according to symptom score, or worsening of preexisting symptoms or apparition of new symptoms.

Efficacy assessment: biological effects of omalizumab

Blood parameters such as tryptase and total IgE levels were analyzed as in daily practice in the different centers. They were collected at diagnosis, and in some cases before and during treatment with omalizumab.

Safety assessment

All physicians following patients under omalizumab therapy were requested to report all adverse events occurring under therapy, following the in-law daily practice reporting system.

Statistical analyses

All analyses were performed with the GraphPad Prism 7.00 software. Differences in the symptom score between baseline and follow-up under omalizumab therapy were calculated using the Wilcoxon signed rank test. Tests were performed 2-tailed. Mean tryptase and total IgE levels were compared with paired Student’s t tests. Reported P values were considered statistically significant if below .05.

RESULTS

Patients

Fifty-five patients with a confirmed diagnosis of mast cell disorder according to the WHO criteria and treated with omalizumab were included in this study. Median age at diagnosis was 41 years (2-87 years), and median age at treatment with omalizumab was 48 years (17-93 years).

The diagnoses were ISM (29 patients, 52.7%), MCAS (15 patients, 27.3%), and CM (11 patients, 20%). Of 55 patients, 49 were evaluated for *KIT* mutation; *KIT* D816V mutation was found in 27 of 49 patients (55.1%): 23 of 28 patients (82.1%) with ISM, 3 of 9 patients (33.3%) with CM, and 1 of 12 patients (8.3%) with MCAS.

A large majority of these patients already received all classical therapies against symptoms related to MCA, including antihistamines, cromolyn sodium, or leukotriene inhibitors. Of 55 patients, 45 (82%) continued at least one of the classical therapies that they were receiving before initiation of omalizumab. Some patients already received multiple tyrosine kinase inhibitors, immunomodulatory, or cytoreductive treatments. Patients’ characteristics at inclusion, including previous treatments, are detailed in Table I.

Best response rates

Among the 55 patients, we observed a CR for 1 patient (1.8%), a MR for 30 patients (54.5%), and a PR for 12 patients (21.8%), resulting in symptom improvement for 43 patients (overall response rate of 78.2%).

TABLE I. Patients' characteristics (N = 55)

Patients' characteristics	N = 55
General characteristics	
Age at diagnosis, y, median (range)	41 (2-87)
Age at omalizumab treatment, y, median (range)	48 (17-93)
Time from diagnosis to omalizumab treatment, median (range)	3 y (2 mo to 37 y)
Sex ratio (M/F)	0.44
Disease classification in the whole cohort	
Primary MCAS (N = 41)	
Indolent systemic mastocytosis (ISM), N (%)	29 (52.7)
<i>KIT</i> D816V mutation positive, n	23
<i>KIT</i> D816V mutation negative, n	5
<i>KIT</i> D816V mutation not evaluated, n	1
Cutaneous mastocytosis (CM), N (%)	11 (20)
<i>KIT</i> D816V mutation positive, n	3
<i>KIT</i> D816V mutation negative, n	6
<i>KIT</i> D816V mutation not evaluated, n	2
Mast cell activation syndrome (MCAS), N (%)	15 (27.3)
<i>KIT</i> D816V mutation positive (=MMAS), n	1
Idiopathic MCAS (N = 14)	
<i>KIT</i> D816V mutation negative, n	11
<i>KIT</i> D816V mutation not evaluated, n	3
WHO 2016 criteria	
Multifocal dense infiltrates of MCs (≥ 15 MCs in aggregates) in BM biopsies and/or in sections of other extracutaneous organ(s) (n = 23 evaluated)	13 (56%)
25% of all MCs are atypical cells (type I or type II) on BM smears or are spindle-shaped in MC infiltrates detected on sections of visceral organs (n = 39 evaluated)	39 (44%)
<i>KIT</i> point mutation at codon 816 in the BM or another extracutaneous organ (n = 49 evaluated)	27 (55.1%)
MCs in BM or blood or another extracutaneous organ exhibit CD2 and/or CD25 (n = 34 evaluated)	18 (53%)
Baseline serum tryptase level >20 ng/mL (n = 55 evaluated)	21 (38%)
Disease presentation	
Involved skin, N (%)	35 (63.6)
Maculopapular cutaneous mastocytosis, N (%)	31 (56.4)
Histological criteria, N (%)	28 (50.9)
<i>KIT</i> D816V mutation, N (%) (n = 22 evaluated)	14 (63.6)
Involved bone marrow, N (%) (n = 49 evaluated)	28 (57.1)
Histological criteria, N (%)	13 (26)
Cytological criteria, N (%)	16 (32.7)
Phenotypical criteria, N (%)	17 (34.7)
<i>KIT</i> D816V mutation, N (%)	22 (44.9)
Decreased bone density, N (%)	17 (30.9)
Tryptase and total IgE levels at diagnosis (N = 15)	
Tryptase, ng/mL, mean (range)	30.1 (2.5-145)
Total IgE, UI/mL, mean (range)	151.2 (2-1616)
Previous lines of therapy	
Symptomatic therapies	55 (100)
H2 antihistamine, N (%)	50 (90.9)
H1 antihistamine, N (%)	49 (89)
Montelukast, N (%)	39 (70.9)
Sodium cromoglycate, N (%)	27 (49)
Cytoreductive or targeted therapies (restricted to mastocytosis patients)	17 (30.9)
Cladribine, N (%)	11 (20)
Masitinib, N (%)	8 (14.3)
Imatinib, N (%)	5 (8.9)
Rapamycin, N (%)	3 (5.4)
Interferon, N (%)	2 (3.6)

BM, Bone marrow; MC, mast cell; WHO, World Health Organization.

TABLE II. Response rates

Response categories	All patients (N = 55)	Primary MCAS (N = 41)				Idiopathic MCAS (N = 14)
		All (N = 41)	ISM (N = 29)	CM (N = 11)	MMAS (N = 1)	
Best response						
ORR, N (%)	43 (78.2)	34 (82.9)	23 (79.3)	10 (90.9)	1 (100)	9 (64.3)
CR, n (%)	1 (1.8)	1 (2.4)	1 (3.4)	0	0	0
MR, n (%)	30 (54.5)	22 (53.7)	16 (55.2)	5 (45.45)	1	8 (57.1)
PR, n (%)	12 (21.8)	11 (26.8)	6 (20.7)	5 (45.45)	0	1 (7.1)
No response, N (%)	12 (21.8)	7 (17.1)	6 (20.7)	1 (9.1)	0	5 (35.7)
Response at the last follow-up						
Persistent ORR, N (%)	32 (58.2)	25 (61)	17 (58.6)	7 (63.6)	1 (100)	7 (50)
CR, n (%)	1 (1.8)	1 (2.4)	1 (3.4)	0	0	0
MR, n (%)	23 (41.8)	17 (41.5)	12 (41.4)	4 (36.3)	1	6 (42.9)
PR, n (%)	8 (14.5)	7 (17.1)	4 (13.8)	3 (27.3)	0	1 (7.1)
No persistent response, N (%)	23 (41.8)	16 (39)	12 (41.4)	4 (36.3)	0	7 (50)
No response, n (%)	12 (21.8)	7 (17.1)	6 (20.7)	1 (9.1)	0	5 (35.7)
Loss of response, n (%)	4 (7.3)	3 (7.3)	2 (6.9)	1 (9.1)	0	1 (7.1)
Intolerance, n (%)	3 (5.4)	3 (7.3)	1 (3.4)	2 (18.2)	0	0
Lost from follow-up, n (%)	4 (7.3)	3 (7.3)	3 (10.3)	0	0	1 (7.1)

CM, Cutaneous mastocytosis; CR, complete response; ISM, indolent systemic mastocytosis; MCAS, mast cell activation syndrome; MMAS, monoclonal MCAS; MR, major response; ORR, overall response rate; PR, partial response.




FIGURE 1. Follow-up of responses in the whole cohort (N = 55).

The overall response rate was 82.9% among the 41 patients with primary MCAS, and 64.3% among the 14 patients with idiopathic MCAS. Detailed response rates are presented in Table II.

Time to first response and duration of response

Median time to response was 2 months and median time to best response was 6 months. Regarding specific symptoms improvement, median time to first symptom improvement was 1




FIGURE 2. Symptoms improvement in the whole cohort (N = 55). Comparison of the symptom score before and under omalizumab therapy: P value: ns >0.05; *P < .05; **P < .01; ***P < .001.

month (1-3 months) for general vasomotor symptoms (anaphylaxis, malaise, palpitations) and improvement required 2 to 3 months for all the others symptoms (1-10 months).

At the last follow-up, 32 patients (58.2%) remained on omalizumab therapy. The median duration of omalizumab therapy was 9 months for the whole cohort and 11 months for responding patients, that is, reaching at least a PR (2-36 months). The median duration of therapy was 2 months for nonresponding patients, 10 months for patients in PR, 11 months in patients with MR, and 17 months for the patient in CR.

Response was persistent in most responding patients, with a sustained response of at least 3 months in 33 of 43 patients (76.7%). Only 4 patients lost their acquired response under omalizumab, after 2 to 13 months of treatment.

Among the 43 responding patients, 11 have stopped therapy because of loss of response (4 patients), intolerance (3 patients), loss from follow-up (2 patients), and pregnancy intent (2 patients).

The 12 patients who did not respond to omalizumab all stopped treatment, after 1 to 6 months: 10 patients (83.3%) stopped for lack of efficacy, whereas 2 patients (16.7%) stopped for intolerance. Follow-up data are summarized in Figure 1.

Separated follow-up data for patients with primary MCAS (ISM + CM + MMAS) and nonclonal idiopathic MCAS patients are presented in Figures E1 and E2 (available in this article's Online Repository at www.jaci-inpractice.org).

Response rate at the last follow-up

At the last follow-up, 32 patients were still on therapy. Among these 32 patients, 1 patient was still in CR (1.8%), 23 in MR (41.8%), and 8 in PR (14.5%), resulting in a persistent overall response rate of 58.2%. Detailed final response rates are presented in Table II.

Dose modifications

In 15 of 55 patients (27.3%), a dose escalation was prescribed to try to improve symptom control with omalizumab, according to CEREMAST initial recommendations (up to 300 mg every 15 days for 14 patients, and up to 600 mg every 15 days for 1 patient, which was not a recommended schedule and without objective measures to substantiate efficacy). Among these 15 patients, 14 patients (93%) improved their response, with 6 patients (40%) reaching an MR and 8 patients (53.3%) improving their PR.

In our cohort, 3 patients (5.5%) had a reoccurrence of symptoms before the following dose of omalizumab administered every 2 weeks. In these patients, omalizumab's therapy was modified to a weekly schedule, to reduce the dose interval to 1 week—this weekly schedule is however not Food and Drug Administration (FDA) approved and should not be prescribed outside of a clinical trial. Among these 3 patients, 2 patients improved their response, reaching 1 MR and 1 PR, and 1 patient was not improved with closer administration and stopped omalizumab.

Symptoms improvement

Symptoms and numbers of patients with each symptom are indicated in [Figure 2](#) for patients with ISM and MCAS. The mean number of symptoms per patient was 11. Omalizumab was dramatically effective on all general and superficial vasomotor symptoms, and on most gastrointestinal or urinary symptoms. Omalizumab was also, but often partially, effective on most neuropsychiatric symptoms. Some patients had an improvement of their musculoskeletal pains or headaches. Clinical efficacy data are presented in [Figure 2](#).

We performed separate analyses for symptoms improvement in patients with primary MCAS (ISM + CM + MMAS) and nonclonal idiopathic MCAS patients ([Figures E3](#) and [E4](#), available in this article's Online Repository at www.jaci-inpractice.org). The response profile to omalizumab therapy does not seem to be different between these entities, except for some symptoms with only low number of patients leading to lower statistical power.

Safety

Overall, safety profile was acceptable. Sixteen patients (29%) presented side effects, among whom 5 patients interrupted omalizumab therapy in relation to these side effects. One patient (1.8%) developed a severe adverse event with edema of the larynx and dyspnea 30 minutes after the first injection of omalizumab. Symptoms were controlled after corticosteroids, antihistamine, and β_2 mimetics therapy, but persisted moderately around 3 weeks according to the patient. Three patients (5.5%) presented a significant "flare" effect with accentuation of their symptoms on therapy, requiring omalizumab discontinuation. Other side effects included fatigue (3 patients), fever (3 patients), headache (2 patients), malaise (2 patients), nausea (2 patients), abdominal pain (2 patients), bleeding (increased menstruations and epistaxis for 1 patient, ecchymosis for 1 patient), pruritus (1 patient), local rash (1 patient), and sweating (1 patient).

Biological effects

Blood tests during therapy were not mandatory in this survey, but 15 patients were tested for serum tryptase before and on omalizumab therapy and 15 patients were tested for serum total IgE level before and on omalizumab therapy.

We did not observe any significant modification of the tryptase level on therapy with omalizumab, with a mean value of 30.3 ng/mL before omalizumab and 32 ng/mL on therapy (after at least 3 months of treatment).

We observed an increase in total IgE levels on therapy, with a mean value of 235.1 UI/mL (3.5-1616 UI/mL) before omalizumab and 772.8 UI/mL (6.6-4356 UI/mL) on therapy. Among the 15 tested patients, 11 (73.3%) presented an increase of the total IgE level, whereas the 4 remaining patients (26.7%) presented stable total IgE levels. The evolution of total IgE levels was not correlated with treatment efficacy or tolerance in this small tested subgroup of patients.

Tryptase and total IgE level evolutions on therapy are presented in [Figure E5](#) (available in this article's Online Repository at www.jaci-inpractice.org).

DISCUSSION

This study presents data on the efficacy and safety of omalizumab in mast cell disorders, mainly primary MCAS (ISM, CM,

and MMAS) and nonclonal idiopathic MCAS. We included 55 patients in this analysis, which is, to our knowledge, the largest cohort to date because only 29 patients with SM-treated omalizumab have been reported so far, in 10 different series.¹²⁻²¹

We observed an overall response rate of 78.2% in our series, which is in line with the overall response rate of 78.6% recently published by Broesby-Olsen et al²¹ in their 14-patient cohort.

In this series and when compiling single-case observations, omalizumab seemed especially efficient on recurrent anaphylaxis. In our study, we observed that omalizumab had a very positive effect on all general and superficial vasomotor symptoms, including but not restricted to anaphylaxis, and on most gastrointestinal or urinary symptoms. Regarding anaphylaxis, 13 of 14 patients had an improvement of their symptoms, reaching independence of epinephrine after beginning of omalizumab, but anaphylaxis worsened in 1 patient, which remains unexplained.

Efficacy seems more modest for musculoskeletal pains, headaches, or neuropsychiatric symptoms, yet a few patients significantly improved their symptoms on therapy. These results were similar to those reported by Broesby-Olsen et al:²¹ in their series, the lowest response rate was observed for musculoskeletal pains and neuropsychiatric symptoms.

In our study, omalizumab's efficacy was rapidly observed with a median time to first response of 2 months and a median time to best response of 6 months. Time to response nevertheless ranged from 1 to 10 months, depending on the patient and on the symptom considered. Consistently with available data, the most rapid effect of omalizumab was observed on general vasomotor symptoms, including anaphylaxis. We also observed persistent responses, with an ongoing maximum duration of 36 months at the last follow-up. Only 4 patients lost their response, after 2 to 13 months of treatment.

Interestingly, we observed a possible improvement of symptoms with dose adjustment and/or closer administration. Even if we did not observe a clear relationship between omalizumab dosing and depth of response in the whole cohort, these observations claim for a dosing effect, which seems variable over time and remains to be explored.

With respect to omalizumab's safety, a "flare" effect has previously been described at the beginning of therapy in some patients with mastocytosis.²⁰ Among our 55 patients, 3 patients presented a similar "flare" effect, which has rapidly resolved without sequelae. However, in 1 patient, the flare effect was severe with edema of the larynx and dyspnea occurring 30 minutes after the first injection. Apart from this case, safety profile was acceptable, with mainly mild side effects yet leading to termination of the treatment in 5 patients (9%). Broesby-Olsen et al²¹ also reported an overall favorable tolerance of omalizumab, with subjective side effects of moderate severity in 3 patients, leading to termination of the treatment in 2 of 14 patients (14.3%). Although omalizumab's safety profile appears manageable in these series, the rate of side effects seems higher than expected as compared with other diseases such as chronic idiopathic/spontaneous urticaria.²⁴ However, most of severe adverse events occurred after the first injection, which justifies the need for at least day care hospitalization at the beginning of therapy.

Concerning omalizumab's biological effects, similarly to Broesby-Olsen et al,²¹ we did not find any improvement in tryptase levels under therapy, demonstrating as expected that

anti-IgE therapy is not cytoreductive. We observed an increase in total IgE levels in 11 patients among the 15 tested patients. This effect might be due to stabilization of total IgE (which includes free and omalizumab-bound fractions), as previously reported in allergy patients²⁵ and in chronic spontaneous urticaria.²⁶ Total IgE levels did not seem to correlate with clinical efficacy nor tolerance in our series. In allergic diseases already routinely treated with omalizumab, a reduction of inflammatory mediator release by omalizumab requires a 95% reduction in serum-free IgE levels to modify allergen responses via receptor down-regulation.^{25,27,28} Therefore, in allergic asthma, doses of omalizumab are adapted to the serum total free IgE level and body weight to achieve this reduction in free IgE.^{29,30} In symptomatic chronic idiopathic/spontaneous urticaria, which is not a classic allergen-driven disease, dose of omalizumab is fixed and measurement of the total or free IgE level under therapy is not necessary.^{9,24,31,32} Omalizumab's mechanism of action in symptomatic chronic idiopathic/spontaneous urticaria is however not entirely understood.^{26,33} Further studies remain necessary to better understand how omalizumab therapy results in improvement of mast cell disorders symptoms, and whether and how free or total IgE levels are correlated with clinical efficacy.

There are some limitations to our study, mainly due to the absence of use of a validated scoring test as well as quality of life assessment in this real-life evaluation. Moreover, as this was not a randomized study, patients were all aware of the treatment that they were given. Some of the responses, and especially temporary responses, may thus be due to a placebo effect. It should also be noted that dosing of omalizumab was not adapted on the serum total IgE level nor on body weight, and that some schedules of treatment used in our study (dose escalation and weekly schedule) are not recommended in FDA approval for asthma and chronic urticaria. Despite these limitations, this study provides valuable information on omalizumab therapy in patients with mast cell disorders, in which clinical experience is very limited. A few recommendations could directly derive from our real-life experience: (1) omalizumab can improve all symptoms but is most effective on general and superficial vasomotor and gastrointestinal symptoms; (2) efficacy is usually quick and persistent in responding patients; (3) even if rare, the risk of severe side effects exists at therapy initiation and thus the first administration(s) should be performed in-hospital; and (4) in case of insufficient efficacy, increasing the dose up to 300 mg every 15 days can improve the response in majority of the cases.

Acknowledgments

RL, GF, LF, SB, DC, LL, JR, MA, OL, and OH conceptualized and designed the study. RL, GF, LT, MV, CBL, and LL collected and assembled the data. RL, GF, JR, MA, OL, and OH analyzed and interpreted the data. RL, GF, JR, MA, OL, and OH wrote the original draft of the manuscript. RL, GF, and OH reviewed, edited, and finally validated the manuscript.

REFERENCES

- Metcalfe DD. Mast cells and mastocytosis. *Blood* 2008;112:946-56.
- Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. *J Allergy Clin Immunol* 2006;117:1214-25. quiz 26.
- Galli SJ, Grimaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. *Nat Rev Immunol* 2008;8:478-86.
- Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. *Cancer Res* 2017;77:1261-70.
- Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. *Int Arch Allergy Immunol* 2012;157:215-25.
- Siebenhaar F, Akin C, Bindslev-Jensen C, Maurer M, Broesby-Olsen S. Treatment strategies in mastocytosis. *Immunol Allergy Clin North Am* 2014;34:433-47.
- Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jasse E, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. *Lancet* 2017;389:612-20.
- Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. *PLoS One* 2008;3:e2266.
- Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med* 2013;368:924-35.
- Kawakami T, Blank U. From IgE to omalizumab. *J Immunol* 2016;197:4187-92.
- Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. *Allergy* 2017;72:519-33.
- Lieberoth S, Thomsen SF. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab. *Case Rep Med* 2015;2015:903541.
- Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. *J Allergy Clin Immunol* 2007;119:1550-1.
- Kibsgaard L, Skjold T, Deleuran M, Vestergaard C. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. *Acta Derm Venereol* 2014;94:363-4.
- Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O'Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. *Allergy* 2010;65:926-7.
- Molderings GJ, Raithel M, Kratz F, Azemar M, Haenisch B, Harzer S, et al. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. *Intern Med* 2011;50:611-5.
- Kontou-Fili K, Filis CI. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. *Allergy* 2009;64:1384-5.
- Siebenhaar F, Kuhn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. *J Allergy Clin Immunol* 2007;120:213-5.
- Pitt TJ, Cisneros N, Kalicinsky C, Becker AB. Successful treatment of idiopathic anaphylaxis in an adolescent. *J Allergy Clin Immunol* 2010;126:415-6. author reply 6.
- Jandus P, Hausmann O, Haeblerli G, Gentinetta T, Mueller U, Helbling A. Unpredicted adverse reaction to omalizumab. *J Investig Allergol Clin Immunol* 2011;21:563-6.
- Broesby-Olsen S, Vestergaard H, Mortz CG. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. *Allergy* 2018;73:230-8.
- Garcelon N, Neuraz A, Salomon R, Faour H, Benoit V, Delapalme A, et al. A clinician friendly data warehouse oriented toward narrative reports: Dr. Warehouse. *J Biomed Inform* 2018;80:52-63.
- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016;127:2391-405.
- Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bulbul Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. *J Invest Dermatol* 2015;135:67-75.
- Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. *J Immunol Methods* 2005;303:81-91.
- Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin. *Theranostics* 2017;7:1266-76.
- MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(ε)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. *J Immunol* 1997;158:1438-45.

28. Saini SS, MacGlashan DW Jr, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. *J Immunol* 1999;162:5624-30.
29. Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas AG, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. *J Autoimmun* 2014;51:89-98.
30. Steiss JO, Schmidt A, Rudloff S. Monitoring of omalizumab therapy by measuring free IgE using a bedside immunoassay. *Clin Lab* 2015;61:31-7.
31. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. *J Allergy Clin Immunol* 2013;132:101-9.
32. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. *J Allergy Clin Immunol* 2011;128:567-573.e1.
33. Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. *J Allergy Clin Immunol* 2015;135:337-42.

ONLINE REPOSITORY




FIGURE E1. Follow-up of responses for patients with indolent systemic mastocytosis + monoclonal mast cell activation syndrome (N = 41).




FIGURE E2. Follow-up of responses for patients with idiopathic mast cell activation syndrome (N = 14).




FIGURE E3. Symptoms improvement for patients with indolent systemic mastocytosis + monoclonal mast cell activation syndrome (N = 41). **P* < .05; ***P* < .01; ****P* < .001.




FIGURE E4. Symptoms improvement for patients with idiopathic mast cell activation syndrome (N = 14). **P* < .05.




FIGURE E5. Biological parameters before and after omalizumab treatment.

Reproduced with permission of copyright owner. Further reproduction prohibited without permission.